Malin Corporation PLC Immunocore appoints Chief Executive Officer (3036M)

TIDM0Y71

RNS Number : 3036M

Malin Corporation PLC

07 January 2019

Malin Corporation plc

("Malin")

Immunocore appoints Bahija Jallal as Chief Executive Officer

   -     Malin owns approximately 10% of Immunocore, a Malin Priority Portfolio Asset - 

Dublin-Ireland, 7 January 2019: Malin Corporation plc (ISE:MLC), a company investing in highly innovative life sciences companies, is pleased to note that Immunocore has appointed Bahija Jallal as Chief Executive Officer and Director of the Board.

Bahija Jallal joins from AstraZeneca where she was President and head of its global biologics research and development unit, MedImmune. She was a member of the senior executive team at AstraZeneca reporting to the CEO. During her time at MedImmune, she oversaw significant growth in the AstraZeneca biologics pipeline across a range of disease areas.

"Bahija Jallal's appointment as CEO of Immunocore strengthens the company's management team and signals that it is entering a period of significant clinical and commercial maturity," said Jean-Michel Cossery, Non-Executive Director of Malin and Malin's Immunocore Board designate. "With significant leadership experience and an impressive scientific pedigree, she is ideally suited to lead Immunocore at this exciting time as it focuses on the approaching Biologics License Application submission for its lead asset, IMCgp100 and progressing its broad pipeline. Immunocore is a Malin Priority Portfolio Asset and Bahija's appointment will support this company's momentum towards the creation of value for patients and investors."

Malin owns approximately 10% of Immunocore and carried its investment in Immunocore at EUR85.1 million at 30 June 2018 in its portfolio fair value estimate under International Private Equity Valuation guidelines.

A copy of Immunocore's press release is available to view here: https://www.immunocore.com/news-hub/news

ENDS

For further information, please contact:

Malin

Jessica Bergin, Director of Investor Relations & External Reporting

Tel: [phone]

[e-mail]

Consilium Strategic Communications (Financial PR)

Mary-Jane Elliott / Jonathan Birt

Tel: [phone]

[e-mail]

Powerscourt (Ireland PR)

Eavan Gannon

Tel: [phone]

[e-mail]

Davy Corporate Finance (ESM Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: [phone]

About Malin Corporation plc

Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAUGURAGUPBPGQ

(END) Dow Jones Newswires

January 07, 2019 02:00 ET (07:00 GMT)